Syndax readies its 2nd IPO attempt during a market tempest
24 February 2016
Looking to cash in on its eventful past year, Syndax is upping its bet on a turbulent market with an IPO that will seek to garner about $66 million. The last time Syndax made a try at an IPO, it set out for a $60 million windfall. But this time, it's looking to trade on the rep of its new, high-profile CEO--AstraZeneca vet Briggs Morrison--and a string of partnerships with a who's who in immuno-oncology by selling 4.4 million shares at $14 to $16 per share. At most, it could gain up to $70 million, though the odds against a top-of-the-range response are intimidating.
Groundbreaking STI test can detect chlamydia in 30 minutes
19 February 2016
The Atlas io system was created by the University of Bath's spin-off biotech company Atlas Genetics in 2005. It has now won approval from the EU to be sold. The development means that patients can be tested and treated for the disease within a single clinic visit.
University of Bath biotech spin-out wins EU approval for ground-breaking chlamydia test
08 February 2016
A small biotech that started life at the University of Bath has won approval from European regulators to sell a device that tests for the sexually transmitted disease chlamydia in just 30 minutes.
Blood Test Offers An Amazing View Of Metastatic Prostate Cancer Cells
04 February 2016
A few months ago, I met with Murali Prahalad, CEO of Epic Sciences (San Diego). We discussed the company’s methods of processing blood samples to store, identify and examine circulating tumor cells (CTCs). Since then I’ve been following reports on Epic’s method and other, competing CTC platforms.
Biomarker Discovery Gets a Fix on Cancer
01 February 2016
ust as signposts provide information, direction, and guidance, so too cancer biomarkers can better reveal the complex, dynamic, and heterogeneous landscape of malignancies. Such information is critical for creating better cancer diagnostics, prognostics, and therapeutics, but the journey to find just the right biomarker is often a long and winding road.
Subscribe to Cancer Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies
28 January 2016
Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.
Epic Sciences, Station X Link Up to Analyze CTC Data for CDx Development
25 January 2016
Epic Sciences has announced it will use Station X's GenePool platform as part of data analysis for its collaborations with pharmaceutical companies to develop circulating tumor cell-based companion diagnostics.
Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration
22 January 2016
Georgia Bio announced its 2016 Deals of the Year for pharmaceutical, biotechnology, healthcare IT and medical device companies in the following categories – private financing, joint ventures, initial public offering, mergers, acquisitions and economic development – reflecting a broad range of activity. The annual Deal of the Year awards recognize transactions by life sciences companies in Georgia such as financings, partnering agreements and government grants that are significant to the state’s industry development.
20 January 2016
Targeted toward cracking the code to treating disease resistance in tumor changes, Epic Sciences Inc. has partnered with the Penn Medicine Abramson Cancer Center on multiple studies to explore biomarkers, identified by the analysis of circulating tumor cells (CTCs) at a single-cell resolution. This process is predictive of response to personalized cancer therapeutics—and a precursor to the future of oncology.
19 January 2016
Out of seven billion people on this earth, no two people are the same. Companion diagnostics (CDx) providers argue their medicines shouldn't be the same either. In a world where someone can customize their sandwich, sneakers and even their physical appearance, the healthcare industry has realized one-size-fits-all treatments are no longer a good fit.
21 September 2023
September 21 is World Alzheimer's Day. NovaMedica supports this awareness raising campaign
21 September 2023
12 September 2023
AI-supported spectroscopy delivers superior pharmaceutical packaging QC
03 October 2023
Lymphoma maintenance therapy delivers promise in CTCL
03 October 2023
02 October 2023
The FAS implemented 864 new drug prices in 2022
02 October 2023